Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Résumé
The prognosis of early breast cancer (BC) relies on cell autonomous and immune parameters. The impact of the intestinal microbiome on clinical outcome has not yet been evaluated. Shotgun metagenomics was used to determine the composition of the fecal microbiota in 121 specimens from 76 early BC patients, 45 of whom were paired before and after chemotherapy. These patients were enrolled in the CANTO prospective study designed to record the side effects associated with the clinical management of BC. We analyzed associations between baseline or post-chemotherapy fecal microbiota and plasma metabolomics with BC prognosis, as well as with therapy-induced side effects. We examined the clinical relevance of these findings in immunocompetent mice colonized with BC patient microbiota that were subsequently challenged with histo-compatible mouse BC and chemotherapy. We conclude that specific gut commensals that are overabundant in BC patients compared with healthy individuals negatively impact BC prognosis, are modulated by chemotherapy, and may influence weight gain and neurological side effects of BC therapies. These findings obtained in adjuvant and neoadjuvant settings warrant prospective validation.
Domaines
Sciences du Vivant [q-bio]
Fichier principal
s41418-021-00784-1.pdf (5.71 Mo)
Télécharger le fichier
PMC8408230.html (277.19 Ko)
Télécharger le fichier
| Origine | Publication financée par une institution |
|---|
| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|